Climb Bio (NASDAQ:CLYM) Receives Buy Rating from B. Riley Financial

Key Points

• B. Riley Financial reaffirmed a “buy” rating on Climb Bio and raised its price target to $30 from $26, implying approximately 91% upside from the stock’s $15.71 price.
• Analyst sentiment remains broadly positive, with 14 Buy, one Strong Buy, and one Sell rating; the consensus rating is “Moderate Buy” with an average price target of $25.92.
• Climb Bio shares rose 7.7% to $15.71, while the company reported a quarterly loss of $0.18 per share that exceeded analysts’ expected loss of $0.21. Institutional investors own approximately 69.76% of the stock.

Climb Bio (NASDAQ:CLYM - Get Free Report)'s stock had its "buy" rating reissued by research analysts at B. Riley Financial in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $30.00 price target on the stock, up from their prior price target of $26.00. B. Riley Financial's target price suggests a potential upside of 90.94% from the stock's current price.

CLYM has been the topic of several other research reports. HC Wainwright increased their price target on Climb Bio from $20.00 to $24.00 and gave the stock a "buy" rating in a report on Monday, August 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Climb Bio in a report on Friday, July 17th. BTIG Research lifted their price target on shares of Climb Bio from $20.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday. Guggenheim assumed coverage on shares of Climb Bio in a report on Monday, June 8th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Truist Financial raised their price objective on shares of Climb Bio from $17.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $25.92.

Climb Bio Stock Up 7.7%

NASDAQ:CLYM traded up $1.12 during trading hours on Friday, reaching $15.71. The company had a trading volume of 949,792 shares, compared to its average volume of 991,524. The firm has a market cap of $902.50 million, a price-to-earnings ratio of -18.99 and a beta of 0.09. The business's 50-day simple moving average is $13.99 and its two-hundred day simple moving average is $10.75. Climb Bio has a twelve month low of $1.54 and a twelve month high of $18.33.

Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.03. As a group, equities analysts predict that Climb Bio will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Climb Bio

A number of hedge funds and other institutional investors have recently modified their holdings of CLYM. AQR Capital Management LLC purchased a new stake in shares of Climb Bio during the first quarter valued at approximately $27,000. Goldman Sachs Group Inc. bought a new position in Climb Bio in the 1st quarter valued at $147,000. Marshall Wace LLP purchased a new stake in shares of Climb Bio during the 2nd quarter valued at $46,000. Qube Research & Technologies Ltd purchased a new stake in shares of Climb Bio during the 2nd quarter valued at $43,000. Finally, Jane Street Group LLC purchased a new position in shares of Climb Bio in the 2nd quarter worth about $184,000. Hedge funds and other institutional investors own 69.76% of the company's stock.

Climb Bio News Roundup

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Promising CLYM116 clinical data: A single 320 mg dose produced a roughly 29-day half-life, near-complete APRIL suppression, and 60%–75% suppression of IgA and Gd-IgA1 through 12 weeks. The drug was generally well tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia reported. Climb Bio Announces CLYM116 Phase 1 Data
• Positive Sentiment: Analyst target increases: BTIG Research raised its price target from $20 to $32 and maintained a “buy” rating. Robert W. Baird increased its target from $21 to $25 and kept an “outperform” rating. The revisions indicate that analysts see substantial upside if CLYM116 continues to demonstrate efficacy and safety.
• Positive Sentiment: Pipeline milestones remain ahead: Climb Bio expects initial data from the Phase 2 NAVIGATE-2 trial in the first half of 2027 and plans to initiate a Phase 3 study in 2027. The company’s reported dosing profile could strengthen CLYM116’s competitive position in IgA nephropathy. Oppenheimer on CLYM116 Data
• Neutral Sentiment: High volatility after a major rally: Coverage noted that CLYM had climbed approximately 1,300% over 17 months before recently pulling back. The decline appears to reflect heightened volatility and possible profit-taking rather than a newly disclosed clinical setback, but the stock remains highly sensitive to future trial results.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source